EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Carbamylation is Instrumental in End-Stage Kidney Disease Coagulopathies: The Impact on von Willebrand Factor and Platelet Functionality

Janka Babickova, Urszula Kałucka, Alicja Sochaj-Grzegorczyk, Jan Potempa, Carsten Scavenius, Thomas Knoop, Hans-Peter Marti, Marta Kaminska, Piotr Mydel

Thrombosis and Haemostasis · 01.03.2025 · 125 (03) · 230-240

DOI: 10.1055/a-2373-3792 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.03.2025. Verfasst von Janka Babickova und 8 weiteren Autor:innen. Beteiligte Einrichtung: Broegelmann Research Laboratory, Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: von Willebrand Factor, Blood Platelets, Protein Carbamylation, Kidney Failure, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Narodowe Centrum Nauki, National Science Centre, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic kidney disease (CKD) is a progressive, irreversible, and incurable condition characterized by high morbidity and mortality, affecting approximately one-tenth of the global population. Rise of urea-derived cyanate levels in CKD patients, severalfold higher in comparison to those found in healthy individuals, leads to an increased rate of carbamylation of lysine residues of proteins and peptides. This posttranslational modification plays an important role in the progression of kidney failure but also in the onset of CKD-related complications, including previously reported coagulopathies. In this study, we have explored the impact of carbamylation on the functionality of von Willebrand factor (vWF), a pivotal player in hemostasis, and its implications for platelet adhesion. Materials and Methods We have explored carbamylated vWF's interactions with its partner proteins via ELISA. Mass spectrometry was employed to identify modified lysine residues. Blood platelets isolated from healthy donors were carbamylated, and their activation, binding to endothelium and thromboxane release were evaluated using flow cytometry, adhesion assays and ELISA, respectively.

Results

Using mass spectrometry we detected the vWF's lysine residue smost susceptible to carbamylation. This modification has in turn affected vWF's interactions with its key binding partners: decreased binding to collagen types I/III but increased the affinity to factor FVIII, while its binding to fibrinogen remained unchanged. Carbamylation of vWF impeded vWF-blood platelet binding, but carbamylation of platelets led to their increased thrombin-dependent activation as observed by enhanced phosphatidylserine exposure, improved their binding to vascular endothelium, at the same time decreasing the production of the prothrombotic mediator, thromboxane A2.

Conclusion

Our findings highlight the multifaceted impact of carbamylation on vWF and platelets, disturbing the delicate balance of coagulation cascade. These alterations could contribute to the complex hemostatic imbalance in ESKD, underscoring the need for further research to fully understand these mechanisms and their clinical implications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

von Willebrand FactorBlood PlateletsProtein CarbamylationKidney Failure, ChronicBlood Coagulation DisordersHumansPlatelet AdhesivenessProtein Processing, Post-TranslationalLysineMaleProtein BindingFemaleMiddle Aged

Substanzen

von Willebrand FactorLysine

Autor:innen und Institutionen

  • Broegelmann Research Laboratory, Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway.
  • Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland.
  • Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
  • Department of Medicine, Haukeland University Hospital, Bergen, Norway.
  • Department of Clinical Medicine, Faculty of Medicine, University of Bergen, Bergen, Norway.

Förderung

  • Narodowe Centrum Nauki
  • National Science Centre, Poland

Zitieren

APA

Babickova, J., Kałucka, U., Sochaj-Grzegorczyk, A., Potempa, J., Scavenius, C., Knoop, T., Marti, H. P., Kaminska, M., & Mydel, P. (2025). Carbamylation is Instrumental in End-Stage Kidney Disease Coagulopathies: The Impact on von Willebrand Factor and Platelet Functionality. Thrombosis and Haemostasis, 125(03), 230-240. https://doi.org/10.1055/a-2373-3792

Vancouver

Babickova J, Kałucka U, Sochaj-Grzegorczyk A, Potempa J, Scavenius C, Knoop T, et al. Carbamylation is Instrumental in End-Stage Kidney Disease Coagulopathies: The Impact on von Willebrand Factor and Platelet Functionality. Thrombosis and Haemostasis. 2025;125(03):230-240. doi:10.1055/a-2373-3792

BibTeX
@article{Babickova2025,
  author = {Babickova, Janka and Kałucka, Urszula and Sochaj-Grzegorczyk, Alicja and Potempa, Jan and Scavenius, Carsten and Knoop, Thomas and Marti, Hans-Peter and Kaminska, Marta and Mydel, Piotr},
  title = {Carbamylation is Instrumental in End-Stage Kidney Disease Coagulopathies: The Impact on von Willebrand Factor and Platelet Functionality},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {03},
  pages = {230--240},
  doi = {10.1055/a-2373-3792}
}
Kostenlos starten →